SCHEMBL3669100

SCHEMBL3669100

CNCC(=O)N(C)c1n[nH]c2ccc(-c3cn(CCN4CCOCC4)nn3)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 5/20 0.53
FLT3 P36888 1/20 0.46
IKBKB O14920 1/20 0.44
MAPK13 O15264 1/20 0.44
DAPK3 O43293 1/20 0.44
DYRK3 O43781 1/20 0.44
ROCK2 O75116 1/20 0.44
PRKD3 O94806 1/20 0.44
CDK1 P06493 1/20 0.44
PIM1 P11309 1/20 0.44
PRKACA P17612 1/20 0.44
CDK2 P24941 1/20 0.44
MAPK1 P28482 1/20 0.44
MAPK9 P45984 1/20 0.44
CSNK1D P48730 1/20 0.44
CDK8 P49336 1/20 0.44
CLK2 P49760 1/20 0.44
GSK3B P49841 1/20 0.44
MAPK12 P53778 1/20 0.44
CSNK2A1 P68400 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4291662 0.93 CDC7 (0.46) CDC7FLT3IKBKBMAPK13DAPK3
SCHEMBL3671890 0.87 CDC7 (0.52) CDC7FLT3IKBKBMAPK13DAPK3
SCHEMBL3668981 0.86 DYRK1A (0.52) PIM1GSK3BDYRK1A
SCHEMBL16240936 0.85 CDC7 (0.51) CDC7FLT3IKBKBMAPK13DAPK3
SCHEMBL16240935 0.83 CDC7 (0.62) CDC7FLT3IKBKBMAPK13DAPK3
SCHEMBL3669095 0.79 CDC7 (0.68) CDC7FLT3IKBKBMAPK13DAPK3
SCHEMBL4295544 0.79 CDC7 (0.56) CDC7FLT3IKBKBMAPK13DAPK3
SCHEMBL3799220 0.79 AOC3 (0.46) GSK3BDYRK1A
SCHEMBL3665797 0.75 GSK3B (0.54) GSK3BDYRK1A
SCHEMBL3667833 0.74 CDC7 (0.38) CDC7FLT3IKBKBMAPK13DAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885FLT3 312/4885IKBKB 743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.